Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

Exclusion Criteria

• •Residual diuresis \> 100 mL per day
• •Pregnant or breast-feeding
• •Uncontrolled hypertension \> 180/115 millimetre of mercury (mmHg)
• •Perdialytic hypotension requiring vascular filling \> 100 mL during the last 3 sessions
• •Patients already on parenteral nutrition
• •Patients already on Vitamin K antagonists (VKA) (or prescribed less than one month before inclusion)
• •Patients with allergy to heparin or requiring haemodialysis without anticoagulant (recent haemorrhage)
• •Criteria relating to products/procedures: Patient with
• •* an allergy to egg, soya or peanut proteins or to one of the active ingredients or one of the excipients (glycerol, egg phospholipids for injection, a-tocopherol, sodium oleate (to adjust the pH), water for injection) of Médialipide
• •* Severe hyperlipidaemia or severe lipid metabolism disorder characterised by hypertriglyceridaemia \> 3 mmol/l
• •* Sepsis \< 1 month
• •* Severe liver failure or cholestasis
• •* Known severe coagulopathy
• •* Acute thrombo-embolic events
• •* Fat embolism
• •* Aggravating bleeding diathesis,
• •* Uncompensated metabolic acidosis.
• •* Unstable circulatory state threatening the vital prognosis (collapse and shock),
• •* Unstable metabolic conditions (e.g. severe post-traumatic syndrome, coma of unknown origin),
• •* Acute phase of myocardial infarction or stroke,
• •* Uncorrected disturbances of fluid and electrolyte balance, such as hypokalaemia and hypotonic dehydration.
• •* Decompensated heart failure,
• •* Acute pulmonary oedema.
• •Subject participating in another interventional study involving a drug with an exclusion period still in progress at inclusion.